Travere Therapeutics (TVTX) Stock Falls on Q4 2025 Earnings

Travere Therapeutics Inc. (TVTX) reported fourth-quarter 2025 results.

Total revenue of $129.7 million (up 73.41% year-over-year).

Gross profit of $127.1 million (up 76.00% year-over-year).

Operating loss of $32.4 million (down 46.61% year-over-year).

Net income attributable to common shareholders of $2.7 million (down 104.53% year-over-year).

Diluted earnings per share of $0.03 (down 104.23% year-over-year).

Balance sheet and cash flow highlights:

Cash and cash equivalents of $93.0 million (up 58.94% year-over-year).

Cash from operating activities of $5.0 million (down 113.95% year-over-year).

Capital expenditures of $0.2 million (purchases of property, plant and equipment).

Total liabilities of $490.4 million (down 8.35% year-over-year).

Cost of sales of $2.6 million (essentially flat, up 0.04% year-over-year).

How results compared to expectations:

Revenue came in at $129.7 million versus an estimate of $147.7 million.

Reported diluted EPS was $0.03 versus an estimate of -$0.04.

Market reaction and takeaways:

Shares moved about -3.24% since market close.

The quarter shows strong top-line growth and gross margin expansion, while operating losses persisted and cash generation weakened; the company finished the quarter with a stronger cash balance.

Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.

Travere Therapeutics Inc. Insider Trading Activity

Travere Therapeutics Inc. insiders have traded $TVTX stock on the open market 37 times in the past 6 months. Of those trades, 0 have been purchases and 37 have been sales.

Here’s a breakdown of recent trading of $TVTX stock by insiders over the last 6 months:

ERIC M DUBE (CHIEF EXECUTIVE OFFICER) has made 0 purchases and 6 sales selling 280,087 shares for an estimated $8,673,881.
SANDRA CALVIN (SVP, CHIEF ACCOUNTING OFFICER) has made 0 purchases and 4 sales selling 81,760 shares for an estimated $2,956,155.
WILLIAM E. ROTE (Chief Research Officer) has made 0 purchases and 2 sales selling 72,446 shares for an estimated $2,815,280.
ELIZABETH E REED (Chief Legal Officer and GC) has made 0 purchases and 7 sales selling 40,169 shares for an estimated $1,128,554.
JULA INRIG (CHIEF MEDICAL OFFICER) has made 0 purchases and 6 sales selling 26,211 shares for an estimated $1,009,130.
CHRISTOPHER R. CLINE (CHIEF FINANCIAL OFFICER) has made 0 purchases and 7 sales selling 30,030 shares for an estimated $1,007,726.
PETER HEERMA (CHIEF COMMERCIAL OFFICER) has made 0 purchases and 4 sales selling 20,543 shares for an estimated $709,542.
TIMOTHY COUGHLIN sold 18,000 shares for an estimated $630,601

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

Travere Therapeutics Inc. Hedge Fund Activity

We have seen 156 institutional investors add shares of Travere Therapeutics Inc. stock to their portfolio, and 146 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

FMR LLC added 6,723,715 shares (+232.3%) to their portfolio in Q4 2025, for an estimated $256,913,150
MACQUARIE GROUP LTD removed 4,984,333 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $190,451,363
ARMISTICE CAPITAL, LLC removed 2,960,109 shares (-44.0%) from their portfolio in Q4 2025, for an estimated $113,105,764
STATE STREET CORP added 1,538,827 shares (+47.8%) to their portfolio in Q4 2025, for an estimated $58,798,579
RA CAPITAL MANAGEMENT, L.P. removed 1,150,000 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $43,941,500
FIERA CAPITAL CORP added 874,053 shares (+inf%) to their portfolio in Q4 2025, for an estimated $33,397,565
JENNISON ASSOCIATES LLC removed 828,015 shares (-76.4%) from their portfolio in Q4 2025, for an estimated $31,638,453

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

Travere Therapeutics Inc. Analyst Ratings

Wall Street analysts have issued reports on $TVTX in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

HC Wainwright & Co. issued a "Buy" rating on 11/28/2025
TD Cowen issued a "Buy" rating on 10/31/2025
Wells Fargo issued a "Overweight" rating on 09/11/2025

To track analyst ratings and price targets for Travere Therapeutics Inc., check out Quiver Quantitative's $TVTX forecast page.

Travere Therapeutics Inc. Price Targets

Multiple analysts have issued price targets for $TVTX recently. We have seen 5 analysts offer price targets for $TVTX in the last 6 months, with a median target of $38.0.

Here are some recent targets:

Allison Bratzel from Piper Sandler set a target price of $38.0 on 02/06/2026
Joseph Pantginis from HC Wainwright & Co. set a target price of $47.0 on 11/28/2025
Tyler Van Buren from TD Cowen set a target price of $40.0 on 10/31/2025
Alex Thompson from Stifel set a target price of $25.0 on 09/12/2025
Mohit Bansal from Wells Fargo set a target price of $35.0 on 09/11/2025